Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Quadruplet Regimens Stand Strong in Newly Diagnosed Multiple Myeloma

February 4th 2025

Experts break down emerging data for the use of quadruplet regimens in newly diagnosed multiple myeloma.

Cilta-Cel in Early R/R MM: Evolving CAR T Data from CARTITUDE-4

February 4th 2025

Panelists discuss the latest efficacy data from the CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM), the significance of minimal residual disease (MRD) negativity, and how real-world and patient-reported outcomes influence the decision to use chimeric antigen receptor (CAR) T-cell therapy for early-stage R/R MM. They also compare standard-of-care idecabtagene vicleucel (ide-cel) and cilta-cel in this patient population.

Optimal Strategies for Bridging Therapy for Patients Receiving CAR T in Early R/R MM

February 4th 2025

Panelists discuss their optimal strategies for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T in the treatment of relapsed/refractory multiple myeloma (R/R MM).

Dr Bishop on the Potential Significance of Anito-Cel for the Multiple Myeloma Treatment Paradigm

February 3rd 2025

Michael R. Bishop, MD, discusses the potential significance of anitocabtagene autoleucel for the relapsed/refractory multiple myeloma treatment paradigm.

Dr Landgren on Recent Treatment Paradigm Changes in Multiple Myeloma

February 3rd 2025

C. Ola Landgren, MD, PhD, discusses the rapidly changing treatment paradigm within multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

China's NMPA Approves Isatuximab Plus VRd for Newly Diagnosed, Transplant-Ineligible Myeloma

January 31st 2025

China’s NMPA approved isatuximab plus VRd for newly diagnosed, transplant-ineligible multiple myeloma.

Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel in R/R Multiple Myeloma

January 31st 2025

Pooja Phull, MD, discusses real-world responses and survival outcomes with cilta-cel vs ide-cel in patients with relapsed/refractory multiple myeloma.

Dr Kaddoura on Challenges Integrating Whole Genome Sequencing Into Clinical Practice in Myeloma

January 30th 2025

Marcella Ali Kaddoura, MD, discusses challenges in integrating whole genome sequencing into routine clinical practice for myeloma.

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

January 30th 2025

Dr. Elias K. Mai presents final progression-free survival results from the Phase 3 GMMG-HD7 trial, demonstrating that adding isatuximab to lenalidomide, bortezomib, and dexamethasone (Isa-RVd) significantly improves minimal residual disease negativity and reduces the risk of progression or death in transplant-eligible patients with newly diagnosed multiple myeloma.

Dr Siegel on the Current and Future Role of Mezigdomide in Multiple Myeloma

January 29th 2025

David Samuel Dicapua Siegel, MD, discusses the current and future role for mezigdomide in the multiple myeloma treatment paradigm.

Dr Shah on the Effect of IVIG on Infection Risk in R/R Multiple Myeloma

January 28th 2025

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.

Expert Perspectives: Referrals and Present Challenges with CAR T for Early R/R MM

January 28th 2025

Panelists discuss the challenges and barriers that remain when considering early referral for chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (R/R MM).

Dr Zackon on Next Steps for Evaluating the Real-World Use of Bispecific Antibodies in R/R Myeloma

January 23rd 2025

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

January 22nd 2025

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

January 21st 2025

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

CAR T and Evolving Treatment Paradigms for Early R/R MM

January 21st 2025

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

Dr Banerjee on Bispecific Antibody Treatment De-Escalation Strategies in Relapsed Myeloma

January 20th 2025

Rahul Banerjee, MD, FACP, discusses treatment de-escalation strategies with the use of bispecific antibodies in patients with relapsed multiple myeloma.

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

January 19th 2025

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

January 17th 2025

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.